About Corneal Blindness 

Eye contact1_Shutterstock.jpg

Global Demand

%D7%A8%D7%A7%D7%A2-01_edited.jpg

CorNeat KPro Advantages 

CorNeat KPro is superior to keratoplasty and current keratoprosthetics in the following aspects

Optical Performance

Replicating optimal corneal optics

-

Wide field of view

-

Simplifying the surgical procedure via direct visualization while

enabling future procedures in a similar fashion

 

Healing & Retention

Device integrates to the eye wall using nano-fabric that imitates the native ECM

-

Fast to heal

-

Progressive integration

-

Straight forward post-operation recovery

Scalability 

Relatively simple, 45-minute operation

-

Affordable price

-

No need for tissue

-

No time constraints placed on scheduling of the implantation

Safe 

No need for tissue

-

 Cannot carry any infectious agent including COVID-19

CorNeat KPro

The CorNeat KPro is an artificial cornea, keratoprosthesis (KPro), which provides a long-lasting medical solution for corneal blindness, pathology and injury. The CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue. It is produced using nanoscale chemical engineering, which stimulates cellular growth.

Current biological solutions (keratoplasty), and previous KPros, are either sutured to, or attempt integration with, the native corneal tissue – a tissue that lacks blood vessels and heals very poorly. The CorNeat KPro integrates underneath the conjunctiva, the white part of the eye, a site rich with fibroblasts, which heals quickly and vigorously. 

 

The CorNeat KPro is combined with a novel and relatively simple surgical procedure to provide an efficient, therapeutic, and affordable remedy for millions of people with cornea-related visual impairments and is far superior to any available alternative. 

%D7%A8%D7%A7%D7%A2-01_edited.jpg

Features and Surgical Procedure 

Indications 

Failed keratoplasty 

Corneal indications not suitable for keratoplasty, such as: 

  • Herpes keratitis

  • Corneal degenerations

  • ICE syndrome

  • Aniridia

  • SJS

  • OCP

  • Alkali burns

  • Vascularized cornea

%D7%A8%D7%A7%D7%A2-01_edited.jpg

Regulatory Path

CorNeat Vision designed, produced and tested several versions of the CorNeat KPro, successfully completing the pre-clinical phase which included a groundbreaking 6-months-long study, successfully proving its safety.

 

The CorNeat KPro is planned to begin clinical trials during the second half of 2020, toward FDA (510K) clearance (USA) and CE marking (Europe).

Given the apparent superiority over donor tissue, we are planning to conduct a  study with broader indications including as first line treatment, which will enable us to expand the device's indications for use. At present, the device is expected to achieve the initial clearance in 2022.

In China, where there are over 5 million patients waiting for keratoplasty and only a few thousand transplantations a year, we are planning a study which will facilitate turning the CorNeat KPro into a primary solution for corneal blindness. The study is planned to start in 2021 and will include 60-70 local patients toward the NMPA (previously CFDA) approval (China).

 

The plans above are subject to regulatory approvals and requirements.

 

Product Animation 

 CorNeat KPro
CorNeat KPro
Q&A
%D7%A8%D7%A7%D7%A2-01_edited.jpg

info@corneat.com

Visit us at
4 HaSheizaf St.

Ra'anana, Israel

Join Our Mailing List